USD 750

Product Type

Industry Statistics

Release Date

17 March 2022

Region

North America

Release Year

2022

Table of Contents
    Add a header to begin generating the table of contents

    Description

    A liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for that patient. According to StrategyHelix, the liquid biopsy market in United States is expected to increase by US$ 3.80 billion during 2022-2028, expanding at a CAGR of 11.7% during the forecast period.

    The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for liquid biopsy. The United States liquid biopsy market is segmented on the basis of product, therapy, application, and technology. Based on product, the liquid biopsy market in United States is categorized into kits and reagents, instruments, and tests/services. On the basis of therapy, the liquid biopsy market in United States has been segmented into noninvasive prenatal testing (NIPT), oncology, and others. By application, the liquid biopsy market in United States has been segmented into therapy guidance, diagnosis/screening, and treatment monitoring. Based upon technology, the liquid biopsy market in United States is categorized into NGS, PCR, and others.

    The United States liquid biopsy market is highly competitive. The liquid biopsy market is dominated by key players, which are Exact Sciences Corp., F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., Invitae Corp., Laboratory Corporation of America Holdings (Labcorp), Natera Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Sysmex Inostics Inc.

    The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.


    Report Scope

    Product: kits and reagents, instruments, and tests/services
    Therapy: noninvasive prenatal testing (NIPT), oncology, and others
    Application: therapy guidance, diagnosis/screening, and treatment monitoring
    Technology: NGS, PCR, and others
    Years considered: this report covers the period 2018 to 2028


    Key Benefits for Stakeholders

    – Get a comprehensive picture of the United States liquid biopsy market
    – Identify regional strategies and strategic priorities on the basis of local data
    – Pinpoint growth sectors and trends for investment


    Table of Contents

    1. Market definition
    2. Research methodology
    3. Market data and outlook
    3.1 Market size estimates
    3.2 Forecast
    4. Liquid biopsy market by product
    4.1 Kits and reagents
    4.2 Instruments
    4.3 Tests/services
    5. Liquid biopsy market by therapy
    5.1 Noninvasive prenatal testing (NIPT)
    5.2 Oncology
    5.3 Others
    6. Liquid biopsy market by application
    6.1 Therapy guidance
    6.2 Diagnosis/screening
    6.3 Treatment monitoring
    7. Liquid biopsy market by technology
    7.1 NGS
    7.2 PCR
    7.3 Others
    8. Company profiles
    8.1 Exact Sciences Corp.
    8.2 F. Hoffmann-La Roche AG
    8.3 Guardant Health, Inc.
    8.4 Illumina, Inc.
    8.5 Invitae Corp.
    8.6 Laboratory Corporation of America Holdings (Labcorp)
    8.7 Natera, Inc.
    8.8 QIAGEN N.V.
    8.9 Quest Diagnostics Incorporated
    8.10 Sysmex Inostics Inc.
    9. Appendix
    9.1 About StrategyHelix
    9.2 Disclaimer


    StrategyHelix Black LOGO

    REQUEST SAMPLE

    Please fill out our form and we will get back to you.

    Liquid Biopsy Market in United States 2022

    StrategyHelix Black LOGO

    CUSTOM RESEARCH

    Custom projects can be researched to match your unique needs.

    Liquid Biopsy Market in United States 2022

    login